Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 463

1.

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH.

Osteoporos Int. 2005 May;16(5):510-6. Epub 2004 Aug 18.

PMID:
15322742
2.

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.

Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.

Arch Intern Med. 2004 Oct 11;164(18):2024-30.

PMID:
15477438
4.

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.

Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.

J Bone Miner Res. 2006 Nov;21(11):1785-90.

5.

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA.

J Bone Miner Res. 2003 Jan;18(1):9-17.

6.

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.

N Engl J Med. 2001 May 10;344(19):1434-41.

7.

Reduced risk of back pain following teriparatide treatment: a meta-analysis.

Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH.

Osteoporos Int. 2006 Feb;17(2):273-80. Epub 2005 Sep 2. Review.

PMID:
16142502
8.

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.

J Bone Miner Res. 2005 Sep;20(9):1507-13. Epub 2005 May 2.

9.

Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.

Brixen KT, Christensen PM, Ejersted C, Langdahl BL.

Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):260-70. Review.

10.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, MarĂ­n F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

11.

A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.

Dobnig H.

Expert Opin Pharmacother. 2004 May;5(5):1153-62. Review.

PMID:
15155114
13.

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.

Reid DM, Adami S, Devogelaer JP, Chines AA.

Calcif Tissue Int. 2001 Oct;69(4):242-7.

PMID:
11730260
14.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
15.

Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.

Curr Med Res Opin. 2013 Mar;29(3):195-203. doi: 10.1185/03007995.2012.761956. Epub 2013 Jan 17.

PMID:
23259702
16.
17.

Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.

Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.

Horm Metab Res. 2009 Jul;41(7):559-62. doi: 10.1055/s-0029-1192035. Epub 2009 Feb 9.

PMID:
19204890
19.
20.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744

Supplemental Content

Support Center